Neogen Corporation reports developments tied to its food safety and animal safety businesses, including diagnostic tests, environmental monitoring products, veterinary products and related manufacturing operations. Company updates commonly cover foodborne pathogen detection, Listeria testing, AOAC method certification, Petrifilm manufacturing activity, and product quality or recall matters involving animal health products.
Neogen news also includes quarterly operating results, segment performance in Food Safety and Animal Safety, business transformation updates, leadership and compliance appointments, and governance matters. Its recurring disclosures connect scientific validation, manufacturing execution, customer markets and regulatory interactions across food safety, livestock, and pet health and wellness applications.
Neogen (NASDAQ:NEOG) appointed Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary effective immediately. Ms. Stacey brings more than 25 years of life sciences legal and compliance experience, including over 10 years as a public company chief legal officer and 5 years as a public company board member.
She previously served at Galera Therapeutics and held senior legal roles at Wistar Institute, Antares Pharma, FXI, Auxilium, and Aventis Behring. Ms. Stacey also serves on the board of Context Therapeutics (NASDAQ:CNTX).
Neogen (NASDAQ: NEOG) will release third-quarter fiscal 2026 results before market open on April 9, 2026. Management will host a webcast and conference call the same morning at 8:00 a.m. Eastern to provide a financial overview and business update.
Access details include toll-free and international dial-in numbers, a conference ID, and a live webcast via the company’s Investor Relations webpage; a replay will be available after the call.
Zoetis (NYSE: ZTS) will acquire Neogen's animal genomics business for $160 million, enhancing its Precision Animal Health capabilities.
The purchase adds five global laboratories, expanded genotyping and sequencing platforms, and software tools; Zoetis expects to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.
Neogen (NASDAQ: NEOG) agreed to sell its global genomics business (GeneSeek) to Zoetis for $160 million, subject to customary closing adjustments. The divestiture, part of a portfolio review, is expected to close by the end of Neogen's first half of fiscal 2027 and is subject to regulatory approval and customary closing conditions.
GeneSeek reported approximately $90 million in sales in fiscal 2025. Net proceeds are expected to be used primarily for debt reduction, and Guggenheim Securities acted as exclusive financial advisor.
Neogen (NASDAQ: NEOG) announced a voluntary nationwide recall of all lots within expiry of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution packaged as 2mL/20mg and 10mL/50mg vials due to microbial contamination.
The recall cites reports of adverse events in horses after intraarticular use (inconsistent with labeled topical use). Neogen is working with the FDA and arranging product returns; customers should quarantine recalled product and contact AnimalHealth@neogen.com or 859-254-1221.
Neogen (NASDAQ: NEOG) reported Q2 FY2026 revenue of $224.7M (down 2.8% YoY) with core revenue +2.9% YoY. Net loss was $15.9M (loss per diluted share $(0.07)), while Adjusted Net Income was $22.6M and Adjusted EBITDA was $48.7M with an Adjusted EBITDA margin of 21.7%. Gross margin declined to 47.5% from 49.0% due to tariffs, inventory write-offs and mix. Food Safety core growth was positive; Animal Safety revenue declined 11.8% YoY. Cash was $145.3M with $800.0M debt. Company raised FY2026 guidance to $845M–$855M revenue and ~$175M Adjusted EBITDA.
Neogen (NASDAQ: NEOG) announced two senior leadership appointments in January 2026: Joe Freels as Senior Vice President and Chief Commercial Officer, effective January 5, 2026, and Dr. Tammi Ranalli as Senior Vice President and General Manager, Global Food Safety, effective January 7, 2026.
Dr. Ranalli will hold full P&L responsibility for Neogen’s global Food Safety portfolio and lead global strategy across marketing, R&D, and government/regulatory affairs. Freels will lead global Food Safety commercial strategy, including sales, customer and technical services, regional marketing, and commercial excellence. Both executives join from diagnostics and life‑science companies with commercial and operational experience.
Neogen (NASDAQ: NEOG) will release its second-quarter earnings before the market opens on January 8, 2026. Company executives will host a webcast and conference call the same morning at 8:00 a.m. Eastern to discuss results. Access details include toll-free and international phone numbers, a conference ID 82072, and a live webcast on the company investor relations site at investors.neogen.com. A replay will be available shortly after the call via phone and on the investor website.
Neogen (NASDAQ: NEOG) will participate in two investor conferences on January 14, 2026. The company will appear at the CJS Securities 26th Annual New Ideas for the New Year conference (virtual) and at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, where President and CEO Mike Nassif will present at 5:15 PM Pacific on January 14, 2026.
Live webcasts will be available via Neogen’s Investor Relations webpage at investors.neogen.com under “Events & Presentations.”
Neogen (NASDAQ: NEOG) appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025. Riggsbee will lead Neogen’s global finance organization and join the Executive Leadership Team, reporting to CEO Mike Nassif. To support a smooth changeover, David Naemura is expected to remain through the end of the calendar year.
Riggsbee brings over 25 years of financial leadership in diagnostics and healthcare, most recently serving as CFO of bioMérieux’s $2 billion North American business and previously as CFO at Myriad Genetics; prior roles include LabCorp, GE, and KPMG. He holds degrees from UNC Chapel Hill, North Carolina State, and an MBA from Kellogg.